Longitudinal modeling of age-related memory decline and the APOE ε4 effect

Richard J. Caselli, Amylou C. Dueck, David Osborne, Marwan N. Sabbagh, Donald J. Connor, Geoffrey L Ahern, Leslie C. Baxter, Steven Z Rapcsak, Jiong Shi, Bryan K. Woodruff, Dona E C Locke, Charlene Hoffman Snyder, Gene E Alexander, Rosa Rademakers, Eric M. Reiman

Research output: Contribution to journalArticle

300 Citations (Scopus)

Abstract

BACKGROUND: The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE ε4 allele, those who are heterozygous for the allele, and noncarriers is unknown. METHODS: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE ε4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE ε4 allele, using a mixed model for longitudinal change with age. RESULTS: We analyzed 815 subjects: 317 APOE ε4 carriers (79 who were homozygous for the APOE ε4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele-dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. CONCLUSIONS: Age-related memory decline in APOE ε4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalNew England Journal of Medicine
Volume361
Issue number3
DOIs
StatePublished - Jul 16 2009

Fingerprint

Alleles
Dementia
Alzheimer Disease
Education

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., ... Reiman, E. M. (2009). Longitudinal modeling of age-related memory decline and the APOE ε4 effect. New England Journal of Medicine, 361(3), 255-263. https://doi.org/10.1056/NEJMoa0809437

Longitudinal modeling of age-related memory decline and the APOE ε4 effect. / Caselli, Richard J.; Dueck, Amylou C.; Osborne, David; Sabbagh, Marwan N.; Connor, Donald J.; Ahern, Geoffrey L; Baxter, Leslie C.; Rapcsak, Steven Z; Shi, Jiong; Woodruff, Bryan K.; Locke, Dona E C; Snyder, Charlene Hoffman; Alexander, Gene E; Rademakers, Rosa; Reiman, Eric M.

In: New England Journal of Medicine, Vol. 361, No. 3, 16.07.2009, p. 255-263.

Research output: Contribution to journalArticle

Caselli, RJ, Dueck, AC, Osborne, D, Sabbagh, MN, Connor, DJ, Ahern, GL, Baxter, LC, Rapcsak, SZ, Shi, J, Woodruff, BK, Locke, DEC, Snyder, CH, Alexander, GE, Rademakers, R & Reiman, EM 2009, 'Longitudinal modeling of age-related memory decline and the APOE ε4 effect', New England Journal of Medicine, vol. 361, no. 3, pp. 255-263. https://doi.org/10.1056/NEJMoa0809437
Caselli, Richard J. ; Dueck, Amylou C. ; Osborne, David ; Sabbagh, Marwan N. ; Connor, Donald J. ; Ahern, Geoffrey L ; Baxter, Leslie C. ; Rapcsak, Steven Z ; Shi, Jiong ; Woodruff, Bryan K. ; Locke, Dona E C ; Snyder, Charlene Hoffman ; Alexander, Gene E ; Rademakers, Rosa ; Reiman, Eric M. / Longitudinal modeling of age-related memory decline and the APOE ε4 effect. In: New England Journal of Medicine. 2009 ; Vol. 361, No. 3. pp. 255-263.
@article{409a8e776fb142388e3100e001d74949,
title = "Longitudinal modeling of age-related memory decline and the APOE ε4 effect",
abstract = "BACKGROUND: The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE ε4 allele, those who are heterozygous for the allele, and noncarriers is unknown. METHODS: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE ε4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE ε4 allele, using a mixed model for longitudinal change with age. RESULTS: We analyzed 815 subjects: 317 APOE ε4 carriers (79 who were homozygous for the APOE ε4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69{\%}). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele-dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. CONCLUSIONS: Age-related memory decline in APOE ε4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.",
author = "Caselli, {Richard J.} and Dueck, {Amylou C.} and David Osborne and Sabbagh, {Marwan N.} and Connor, {Donald J.} and Ahern, {Geoffrey L} and Baxter, {Leslie C.} and Rapcsak, {Steven Z} and Jiong Shi and Woodruff, {Bryan K.} and Locke, {Dona E C} and Snyder, {Charlene Hoffman} and Alexander, {Gene E} and Rosa Rademakers and Reiman, {Eric M.}",
year = "2009",
month = "7",
day = "16",
doi = "10.1056/NEJMoa0809437",
language = "English (US)",
volume = "361",
pages = "255--263",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "3",

}

TY - JOUR

T1 - Longitudinal modeling of age-related memory decline and the APOE ε4 effect

AU - Caselli, Richard J.

AU - Dueck, Amylou C.

AU - Osborne, David

AU - Sabbagh, Marwan N.

AU - Connor, Donald J.

AU - Ahern, Geoffrey L

AU - Baxter, Leslie C.

AU - Rapcsak, Steven Z

AU - Shi, Jiong

AU - Woodruff, Bryan K.

AU - Locke, Dona E C

AU - Snyder, Charlene Hoffman

AU - Alexander, Gene E

AU - Rademakers, Rosa

AU - Reiman, Eric M.

PY - 2009/7/16

Y1 - 2009/7/16

N2 - BACKGROUND: The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE ε4 allele, those who are heterozygous for the allele, and noncarriers is unknown. METHODS: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE ε4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE ε4 allele, using a mixed model for longitudinal change with age. RESULTS: We analyzed 815 subjects: 317 APOE ε4 carriers (79 who were homozygous for the APOE ε4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele-dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. CONCLUSIONS: Age-related memory decline in APOE ε4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.

AB - BACKGROUND: The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE ε4 allele, those who are heterozygous for the allele, and noncarriers is unknown. METHODS: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE ε4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE ε4 allele, using a mixed model for longitudinal change with age. RESULTS: We analyzed 815 subjects: 317 APOE ε4 carriers (79 who were homozygous for the APOE ε4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele-dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. CONCLUSIONS: Age-related memory decline in APOE ε4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.

UR - http://www.scopus.com/inward/record.url?scp=67650899270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650899270&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0809437

DO - 10.1056/NEJMoa0809437

M3 - Article

C2 - 19605830

AN - SCOPUS:67650899270

VL - 361

SP - 255

EP - 263

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 3

ER -